CD3-B特定单克隆抗体:一种针对复杂和多因素疾病的新疗法
Shubham Singh1, Sanjesh Rathi1, Sakshi Singh2
1School of Pharmacy, Rai University, Ahmedabad, Gujarat, India.
概括
双特异单克隆抗体 (BsAbs) 通过吸引多个点,提供了先进的治疗选择. CD3双特异性BsAbs是强大的免疫疗法,特别是用于癌症免疫疗法,增强T细胞介导的细胞毒性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 单克隆抗体 (mAbs) 显示出治疗前景,但在向和免疫激活方面存在局限性.
- 双特异单克隆抗体 (BsAbs) 通过同时接触多个抗原来克服这些限制.
- CD3双特异性mAbs是BsAbs的一个关键类别,激活T细胞以向细胞毒性.
研究的目的:
- 审查CD3-双特定单克隆抗体 (BsAbs) 的代表格式.
- 为了阐明CD3-BsAbs. 的作用机制.
- 讨论设计策略,以优化CD3-BsAbs的有效性和安全性.
主要方法:
- 对CD3-双特定单克隆抗体格式的文献综述.
- 对T细胞参与和细胞毒性的作用机制的分析.
- 讨论当前的设计策略和临床应用.
主要成果:
- 介绍了CD3双特异单克隆抗体 (BsAbs) 的几个代表格式.
- 阐明了涉及T细胞激活和细胞溶解的作用机制.
- 设计策略的重点是提高效率,尽量减少不良影响.
结论:
- CD3双特定单克隆抗体 (BsAbs) 是一种强大的免疫治疗策略,特别是在瘤学中.
- 优化设计和机制的理解对于最大化治疗效益至关重要.
- 最近的进展和临床应用突出显示了CD3-BsAbs在医学中的潜力.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
233
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
233